CEL-SCI Quarterly Patient Enrollment In Its Head And Neck Cancer Phase III Trial Increases Eight Fold Over Same Prior Year Period
December 02, 2014 at 08:31 AM EST
CEL-SCI Corporation (NYSE MKT: CVM) today announced that during the past three months it has enrolled 58 patients with advanced primary, ...
